>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
乳腺癌侵袭相关分子的研究热点
作者:王晨飞1  胡浩霖2  吕建鑫2  张亚男2 
单位:1. 东南大学 医学院, 江苏 南京 210009;
2. 东南大学 附属中大医院, 江苏 南京 210009
关键词:乳腺癌 分子标志物 侵袭 综述 
分类号:R737.9
出版年·卷·期(页码):2018·37·第四期(734-738)
摘要:

乳腺癌作为女性高发恶性肿瘤之一,其发病率和死亡率在当代社会一直居高不下。乳腺癌患者五年生存率并不低,但是后期肿瘤的浸润和转移,增加了患者的死亡风险,而抑制乳腺癌的浸润和转移是目前乳腺癌诊治的关键环节。个体的差异导致了乳腺癌细胞浸润存在分子层面的差异。因此,了解乳腺癌侵袭的主要分子、研究其侵袭机制,对乳腺癌的复发、治疗、预后有着重要意义。本文作者对乳腺癌侵袭相关分子的研究进展作一综述。

参考文献:

[1] GILKES D M, BAJPAI S, WONG C C, et al. Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis[J].Mol Cancer Res, 2013,11(5):456-466.
[2] KATOH D, NISHIZUKA M, OSADA S, et al. Fad104, a positive regulator of adipocyte differentiation, suppresses invasion and metastasis of melanoma cells by inhibition of STAT3 activity[J].PLoS One, 2015,10(2):e0117197.
[3] DU H, PANG M, HOU X, et al. PLOD2 in cancer research[J].Biomed Pharmacother, 2017,90:670-676.
[4] EISINGER-MATHASON T S, ZHANG M, QIU Q, et al. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis[J].Cancer Discov, 2013,3(10):1190-1205.
[5] CHEN Y, TERAJIMA M, YANG Y, et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma[J].J Clin Invest, 2015,125(3):1147-1162.
[6] 吴颖,杨继鑫,李南林,等. LOX家族与乳腺癌相关性研究进展[J].中华肿瘤防治杂志,2015,22(17):1412-1416.
[7] van' t VEER L J, DAI H, van de VIJVER M J, et al. Gene expression profiling predicts clinical outcome of breast cancer[J].Nature, 2002,415(6871):530-536.
[8] DOEBAR S C, SIEUWERTS A M, de WEERD V, et al. Gene expression differences between ductal carcinoma in situ with and without progression to invasive breast cancer[J].Am J Pathol, 2017,187(7):1648-1655.
[9] BARCUS C E, HOLT E C, KEELY P J, et al. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells[J].PLoS One, 2015,10(1):e0116891.
[10] SCIMECA M, ANTONACCI C, COLOMBO D, et al. Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers[J].Tumour Biol, 2016,37(4):5427-5435.
[11] LIU F, GU L N, SHAN B E, et al. Biomarkers for EMT and MET in breast cancer:an update[J].Oncol Lett, 2016,12(6):4869-4876.
[12] FELIPE LIMA J, NOFECH-MOZES S, BAYANI J, et al. EMT in breast carcinoma-a review[J].J Clin Med, 2016,5(7).pii:E65.
[13] YU Z, SUN M, JIN F, et al. Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer[J].Oncol Rep, 2015,34(1):165-174.
[14] BOCK C, KUHN C, DITSCH N, et al. Strong correlation between N-cadherin and CD133 in breast cancer:role of both markers in metastatic events[J].J Cancer Res Clin Oncol,2014,140(11):1873-1881.
[15] ZHANG J, LIU D, FENG Z, et al. MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin[J].Biomed Pharmacother, 2016,77:135-141.
[16] HESARI A, MOGHADAM S A G, SIASI A, et al. Tumor-derived exosomes:potential biomarker or therapeutic target in breast cancer?[J/OL]. J Cell Biochem, 2017-08-18. doi:10.1002/jcb.26364.
[17] JIA Y, CHEN Y, WANG Q, et al. Exosome:emerging biomarker in breast cancer[J].Oncotarget, 2017,8(25):41717-41733.
[18] H RASHED M, BAYRAKTAR E, K HELAL G, et al. Exosomes:from garbage bins to promising therapeutic targets[J].Int J Mol Sci, 2017,18(3).pii:E538.
[19] HARRIS D A, PATEL S H, GUCEK M, et al. Exosomes released from breast cancer carcinomas stimulate cell movement[J].PLoS One, 2015,10(3):e0117495.
[20] MENCK K, SCHARF C, BLECKMANN A, et al. Tumor-derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN[J].J Mol Cell Biol, 2015,7(2):143-153.
[21] NISHIDA-AOKI N, OCHIYA T. Multilateral strategies utilizing exosomes for cancer therapy[J].Gan To Kagaku Ryoho, 2017,44(5):367-372.
[22] FANG S, TIAN H, LI X, et al. Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification[J].PLoS One, 2017,12(4):e0175050.
[23] PERROT-APPLANAT M, DI BENEDETTO M. Autocrine functions of VEGF in breast tumor cells:adhesion, survival, migration and invasion[J].Cell Adh Mig, 2012,6(6):547-553.
[24] LIANG L, YUE Z, DU W, et al. Molecular imaging of inducible VEGF expression and tumor progression in a breast cancer model[J].Cell Physiol Biochem, 2017,42(1):407-415.
[25] 胡帅尔,张雅洁,崔玉梅,等. VEGF-A和VEGF-C在乳腺癌组织中的表达及其意义[J].癌症,2005,24(9):1076-1079.
[26] ZHANG Z, LUO G, TANG H, et al. Prognostic significance of high VEGF-C expression for patients with breast cancer:an update meta analysis[J].PLoS One, 2016,11(11):e0165725.
[27] EROGLU A, ERSOZ C, KARASOY D, et al. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer:association with lymph node metastasis[J].Adv Clin Exp Med, 2017,26(2):245-249.
[28] 张劲男,张光波,乔军利,等.慢病毒介导的siRNA干扰乳腺癌MCF-7细胞MIF对VEGF-C表达的影响[J].临床与实验病理学杂志,2015,31(12):1388-1391.
[29] 王春艳. EGFR和VEGF联合检测对评估乳腺癌淋巴结转移的意义[J].中国实验诊断学,2015(3):440-442.
[30] 殷菲,尹莉. 基质金属蛋白酶在肿瘤细胞侵袭和迁移中的作用[J].重庆工商大学学报(自然科学版),2009,26(5):446-450.
[31] REN F, TANG R, ZHANG X, et al. Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients:a systematic review and meta-analysis[J].PLoS One, 2015,10(8):e0135544.
[32] RADISKY E S, RADISKY D C. Matrix metalloproteinases as breast cancer drivers and therapeutic targets[J].Front Biosci (Landmark Ed), 2015,20:1144-1163.
[33] ZUCKER S, HYMOWITZ M, ROLLO E E, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer[J].Am J Pathol, 2001,158(6):1921-1928.
[34] TESTER A M, WALTHAM M, OH S J, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice[J].Cancer Res, 2004,64(2):652-658.
[35] YOUSEF E M, TAHIR M R, ST-PIERRE Y, et al. MMP-9 expression varies according to molecular subtypes of breast cancer[J].BMC Cancer, 2014,14:609.
[36] KATUNINA A I, GERSHTEIN E S, ERMILOVA V D, et al. Matrix metalloproteinases 2, 7, and 9 in tumors and sera of patients with breast cancer[J].Bull Exp Biol Med, 2011,151(3):359-362.
[37] QIAO Z K, LI Y L, LU H T, et al. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma[J].World J Surg Oncol, 2013,11:1.
[38] REMACLE A, McCARTHY K, NOEL A, et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer[J].Int J Cancer, 2000,89(2):118-121.
[39] XU H, LI M, ZHOU Y, et al. S100A4 participates in epithelial-mesenchymal transition in breast cancer via targeting MMP2[J].Tumour Biol, 2016,37(3):2925-2932.
[40] YANG Y, LI D P, SHEN N, et al. TPX2 promotes migration and invasion of human breast cancer cells[J].Asian Pac J Trop Med, 2015,8(12):1064-1070.
[41] KOTEPUI M, PUNSAWAD C, CHUPEERACH C, et al. Differential expression of matrix metalloproteinase-13 in association with invasion of breast cancer[J].Contemp Oncol (Pozn), 2016,20(3):225-228.
[42] McFARLANE S, COULTER J A, TIBBITS P, et al. CD44 increases the efficiency of distant metastasis of breast cancer[J].Oncotarget, 2015,6(13):11465-11476.
[43] ZHANG C, XU Y, HAO Q, et al. FOXP3 suppresses breast cancer metastasis through downregulation of CD44[J].Int J Cancer, 2015,137(6):1279-1290.
[44] TAO Z, SHI A, LU C, et al. Breast cancer:epidemiology and etiology[J].Cell Biochem Biophys, 2015,72(2):333-338.
[45] 褚瑞峰,卢雪珍,刘政红,等. 乳腺癌防治社区干预模式及效果评价研究[J].中国医药科学,2014(4):68-71.
[46] 史奕奕,张亚男. 乳腺癌患者心理状况及相关心理干预措施[J].现代医学, 2017,45(12):1848-1852.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405596 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364